Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

SYRE holding history

Spyre Therapeutics, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

SYRE overviewAll 13F holders of SYREFull Q2 2026 holdings

Shares (Q2 2026)
499,963
Value
$44.4M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of SYRE by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026499,963$44.4M<0.1%+253,244+102.6%AddedHolders
Q1 2026246,719$12.4M<0.1%+63,985+35.0%AddedHolders
Q4 2025182,734$5.99M<0.1%−151,988−45.4%ReducedHolders
Q3 2025334,722$5.61M<0.1%−336,322−50.1%ReducedHolders
Q2 2025671,044$10.0M<0.1%+335,577+100.0%AddedHolders
Q1 2025335,467$5.41M<0.1%+80,211+31.4%AddedHolders
Q4 2024255,256$5.94M<0.1%+11,514+4.7%AddedHolders
Q3 2024243,742$7.17M<0.1%−165,111−40.4%ReducedHolders
Q2 2024408,853$9.61M<0.1%+357,665+698.7%AddedHolders
Q1 202451,188$1.94M<0.1%+51,148+127,870.0%AddedHolders
Q4 202340$861<0.1%−6−13.0%ReducedHolders
Q3 202346$564<0.1%−86−65.2%ReducedConverted for a 1-for-25 splitHolders
Q2 20233,306$1.49K<0.1%−10,350−75.8%ReducedHolders
Q1 202313,656$3.96K<0.1%−66,805−83.0%ReducedHolders
Q4 202280,461$36.2K<0.1%−87,797−52.2%ReducedHolders
Q3 2022168,258$88.0K<0.1%−125,576−42.7%ReducedHolders
Q2 2022293,834$148.0K<0.1%+112,133+61.7%AddedHolders
Q1 2022181,701$418.0K<0.1%−14,517−7.4%ReducedHolders
Q4 2021196,218$932.0K<0.1%+1,993+1.0%AddedHolders
Q3 2021194,225$1.54M<0.1%−1,310−0.7%ReducedHolders
Q2 2021195,535$1.36M<0.1%+84,445+76.0%AddedHolders
Q1 2021111,090$880.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.